Cholesterol blood tests measure several related—but not interchangeable—parts of lipid metabolism. A standard lipid panel usually reports total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides. It also supports calculation of non-HDL cholesterol. Apolipoprotein B (ApoB) and lipoprotein(a), or Lp(a), answer different risk questions and are not automatically included in a standard panel.
This distinction matters because cholesterol and triglycerides travel through the bloodstream inside lipoprotein particles. LDL-C estimates how much cholesterol is being carried in LDL-related particles; non-HDL-C captures cholesterol in all non-HDL particles; and ApoB approximates how many atherogenic particles are circulating. Results should be interpreted with age, blood pressure, smoking status, diabetes, kidney disease, family history, known cardiovascular disease, medications, and other clinical information—not as isolated “good” or “bad” numbers.
This article is for education and does not diagnose disease or replace medical care. Seek urgent medical attention for chest pressure, severe shortness of breath, fainting, new weakness or numbness, or other possible symptoms of a heart attack or stroke. Routine cholesterol testing cannot rule out an acute emergency.
Most first-line cholesterol testing begins with a lipid panel. The panel describes the concentration of cholesterol and triglycerides in a blood sample. It does not directly measure plaque inside an artery or determine a person’s complete cardiovascular risk.
A standard lipid panel generally includes:
From those results, a laboratory or clinician can calculate non-HDL-C by subtracting HDL-C from total cholesterol. Some reports also display ratios or other calculated values. ApoB and Lp(a) require separate orders unless they are included in a specifically named panel.
Cholesterol is a waxy substance used in cell membranes and in the production of steroid hormones and bile acids. Triglycerides are molecules that store and transport energy. Because these lipids do not dissolve freely in water, they travel through blood inside lipoproteins: particles made of lipids and proteins.
The name of a blood test tells you which aspect of that transport system it reflects:
These measurements often move together, but they can disagree. Understanding that disagreement is one reason a targeted ApoB measurement may sometimes clarify risk.
| Measurement | What it represents | Important limitation |
|---|---|---|
| Total cholesterol | Cholesterol carried across several lipoprotein categories | Does not identify which particles account for the total |
| LDL-C | Cholesterol carried in LDL-related particles | Does not directly count atherogenic particles or show plaque |
| HDL-C | Cholesterol carried in HDL particles | A high value does not cancel elevated LDL-C, ApoB, or Lp(a) |
| Triglycerides | Circulating triglyceride concentration | Can be influenced by meals, alcohol, glucose regulation, illness, medications, and genetics |
| Non-HDL-C | Total cholesterol minus HDL-C | Includes cholesterol in all non-HDL particles but does not directly count particles |
| ApoB | Approximate concentration of atherogenic lipoprotein particles | Does not show plaque location, arterial narrowing, or an acute cardiac event |
LDL-C measures the amount of cholesterol carried in LDL-related particles. LDL-containing particles can enter the artery wall and contribute to atherosclerosis. In general, a lower LDL-C means less cholesterol is being carried in these particles and available to enter arterial tissue.
LDL-C remains a central treatment target because extensive evidence shows that lowering atherogenic cholesterol reduces cardiovascular events. Yet the meaning of one result depends on context. A laboratory reference interval is a statistical description of results in a reference population; a risk threshold helps identify a level associated with greater concern; and a treatment goal is a clinical target selected for a specific person. These are not the same thing.
For example, a person with established atherosclerotic cardiovascular disease (ASCVD), diabetes, chronic kidney disease, familial hypercholesterolemia, or another high-risk condition may have a lower LDL-C goal than an otherwise lower-risk adult. The 2026 multisociety dyslipidemia guideline uses risk-based LDL-C and non-HDL-C goals rather than one universal target for everyone.[1]
An LDL-C result cannot show whether plaque is already present, where it is located, or whether an artery is narrowed. For questions about plaque, see what blood tests can—and cannot—tell you about plaque buildup.
Non-HDL cholesterol includes the cholesterol carried in every particle other than HDL. It is calculated from a standard lipid panel:
Non-HDL-C = total cholesterol − HDL-C
For example, if total cholesterol is 210 mg/dL and HDL-C is 50 mg/dL, non-HDL-C is 160 mg/dL. This arithmetic example is not an interpretation or treatment goal.
Non-HDL-C includes cholesterol carried in LDL, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), remnant lipoproteins, Lp(a), and other ApoB-containing particles. That broader coverage can be useful when triglyceride-rich particles are present.
In most settings, non-HDL-C is not a separate blood draw or additional order. It is derived from total cholesterol and HDL-C. Like LDL-C, however, it measures cholesterol mass—not the number of particles carrying that cholesterol.
ApoB is a structural protein found on major atherogenic lipoproteins, including LDL, VLDL remnants, IDL, and Lp(a). Each of these circulating particles carries one ApoB molecule. An Apolipoprotein B Test therefore approximates the concentration of atherogenic particles that can enter the artery wall.
The comparison is easiest to understand this way:
Particles do not all carry the same amount of cholesterol. One person may have fewer cholesterol-rich particles, while another has more cholesterol-depleted particles. Their LDL-C values can look similar even though their ApoB values—and therefore estimated particle counts—differ.
This mismatch is called discordance. It is more likely in people with elevated triglycerides, diabetes, insulin resistance, metabolic syndrome, obesity, or very low LDL-C achieved with treatment. When ApoB and LDL-C are discordant, evidence suggests risk often tracks more closely with ApoB or non-HDL-C than with LDL-C alone.[3]
ApoB is a targeted risk-refinement test, not an automatic requirement for every person. Current guidance identifies it as particularly useful when triglycerides are above 200 mg/dL, diabetes is present, or LDL-C has reached a low treated level but residual particle-related risk may remain. ApoB does not reveal plaque, arterial narrowing, or an acute cardiac event.[1]
| Result | Core question | How obtained | When it adds value |
|---|---|---|---|
| LDL-C | How much cholesterol is in LDL-related particles? | Usually calculated from the lipid panel | First-line assessment and treatment monitoring |
| Non-HDL-C | How much cholesterol is in all non-HDL particles? | Calculated as total cholesterol minus HDL-C | Broad view of atherogenic cholesterol, including remnant cholesterol |
| ApoB | Approximately how many atherogenic particles are present? | Separate blood test | Selected cases of suspected discordance or residual risk |
HDL-C measures the cholesterol carried in HDL particles. A low HDL-C can be associated with insulin resistance, higher triglycerides, tobacco exposure, physical inactivity, and other metabolic risk factors. HDL-C is also used in cardiovascular-risk calculators.
Calling HDL-C “good cholesterol” is incomplete. HDL particles have diverse functions, and the cholesterol concentration inside them does not capture all of those functions. A high HDL-C value does not neutralize elevated LDL-C, ApoB, or Lp(a), and HDL-C should not be interpreted on its own.
HDL-C is also not a stand-alone treatment target. Clinical trials of medications that raised HDL-C have not shown that increasing the number itself consistently lowers cardiovascular events when added to contemporary treatment. Lifestyle measures such as regular physical activity, a heart-supportive dietary pattern, avoiding tobacco, adequate sleep, and weight management when appropriate remain valuable because they improve overall cardiovascular and metabolic health—not simply because they may change HDL-C.[6][8]
Triglycerides are a major form of stored energy. After a meal, triglyceride-rich lipoproteins carry dietary fat through the bloodstream; the liver also produces triglyceride-rich VLDL particles. As these particles are processed, remnant particles remain. Elevated triglycerides can therefore signal a greater burden of triglyceride-rich and remnant lipoproteins, even when LDL-C does not appear markedly elevated.
Triglycerides can rise because of:
A single unexpected elevation may need confirmation under comparable conditions and a review of secondary causes. A clinician may consider a separate Triglycerides Test in a focused follow-up plan, although triglycerides are already included in a standard lipid panel.
Markedly elevated triglycerides require prompt clinical attention. At 500 mg/dL or higher, pancreatitis risk becomes an important concern, and risk rises further at very high levels, particularly around 1,000 mg/dL or above. Those numbers are clinical alert points—not do-it-yourself treatment targets. Severe abdominal pain, vomiting, or other concerning symptoms require urgent evaluation.[1]
LDL-C is usually estimated from total cholesterol, HDL-C, and triglycerides. The familiar Friedewald equation has important limitations, particularly when triglycerides are higher or LDL-C is low. Newer Martin/Hopkins and Sampson/NIH equations generally perform better across a wider range of results, so two laboratories using different equations can report different calculated LDL-C values from the same underlying measurements.[1][7]
A Direct LDL Test may be considered when a calculated result is unavailable or unreliable, or when a direct measurement is specifically requested for a clinical reason. However, routine direct LDL assays also have standardization and accuracy limitations. Current guidance generally favors validated modern LDL-C equations over routine direct measurement.
Direct LDL-C does not replace ApoB or Lp(a): direct LDL still measures cholesterol concentration, ApoB estimates particle number, and Lp(a) identifies a distinct inherited particle.
Fasting is not universally required for clinical lipid assessment. A nonfasting lipid profile is acceptable in many routine settings and can reflect a person’s usual daily state. Fasting can be useful when triglycerides are markedly elevated, when confirming an unexpected result, when an inherited triglyceride disorder is suspected, or when the selected calculation or laboratory order requires it.[1]
Product preparation instructions still control the actual collection. At the time of this review, Ulta’s Lipid Panel Test and individual triglycerides test instruct patients to fast for nine hours; the lipoprotein fractionation NMR product instructs a 12-hour fast; the direct LDL product instructs fasting when it is performed with triglycerides; and the standalone ApoB and Lp(a) pages list no special preparation. Instructions can change, so check the exact product page and order confirmation before collection. Water and medication questions should be handled according to the order instructions and your clinician’s guidance.
When following a trend, comparable conditions help. Record whether you were fasting, recent alcohol intake if relevant, acute illness, medication changes, and the laboratory method when available. A small change under different conditions may not represent a meaningful biological change.
Lipid patterns are clues, not diagnoses. The same pattern can have several causes, and more than one cause may be present.
| Pattern | Possible contributing factors | Useful next question |
|---|---|---|
| Higher LDL-C | Genetics, dietary pattern, hypothyroidism, kidney disease, certain liver conditions, medications, and other secondary causes | Is the result persistent, and is there premature cardiovascular disease in the family? |
| Higher triglycerides | Recent food intake, alcohol, diabetes, insulin resistance, obesity, hypothyroidism, kidney or liver disease, pregnancy, medications, and inherited disorders | Were collection conditions comparable, and are secondary causes controlled? |
| Lower HDL-C | Tobacco exposure, inactivity, insulin resistance, elevated triglycerides, genetics, and other metabolic factors | What does the overall cardiometabolic risk profile show? |
| LDL-C/ApoB discordance | Diabetes, higher triglycerides, metabolic syndrome, obesity, treatment effects, and differences in the cholesterol content of particles | Would ApoB or non-HDL-C change risk assessment or treatment decisions? |
Do not use this table to self-diagnose a thyroid, kidney, liver, genetic, or metabolic disorder. A clinician can assess the pattern alongside symptoms, medical history, family history, medications, and other laboratory results.
Familial hypercholesterolemia (FH) is an inherited condition that causes very high LDL-C from an early age and increases the likelihood of premature cardiovascular disease. In adults, an untreated LDL-C of 190 mg/dL or higher is an important reason to evaluate for severe primary hypercholesterolemia, especially when close relatives had early heart attacks, strokes, or known very high cholesterol.[5]
A single high result does not confirm FH. Evaluation may include repeat testing, exclusion of secondary causes, a detailed family history, physical findings, and sometimes genetic testing. When FH is suspected, clinical evaluation also creates an opportunity for family-based screening. This article is not a substitute for a dedicated FH assessment.
Lp(a) is an ApoB-containing lipoprotein with an additional apolipoprotein(a) component. Its concentration is largely inherited, and it is not included in a standard lipid panel. A Lipoprotein (a) Test should not be treated as another version of LDL-C.
Current guidance supports measuring Lp(a) at least once in adulthood to identify inherited risk that may not be visible on a routine panel. Lp(a) is usually stable and is not a routine marker for monitoring statin response.[1] For units, inherited risk, family implications, and treatment context, read the focused guide to elevated Lp(a) and cardiovascular risk.
Follow-up lipid testing helps answer whether treatment is producing the expected response. Useful comparisons may include:
Interpret trends in light of medication adherence, dose changes, recent illness, weight change, dietary change, alcohol intake, and collection conditions. A result that has not changed as expected is a reason to review the full plan—not proof that a medication “failed.”
For the detailed roles of baseline ALT, follow-up timing, symptom-directed creatine kinase testing, interactions, and safety limitations, see Statin Monitoring Lab Tests: Safer, Smarter Cholesterol Care.
Cholesterol testing measures circulating biomarkers. It cannot:
These limitations are not shortcomings of the tests; they define the questions the tests can answer. A lipid panel helps quantify circulating cholesterol and triglycerides. Imaging, an electrocardiogram, blood-pressure measurement, physical examination, and acute-care testing answer other questions.
More testing is not automatically better. The smallest appropriate set depends on the decision you are trying to make.
| Testing tier | Examples | When it may help | When not to assume it is needed |
|---|---|---|---|
| Common or first-line | Lipid panel | Screening, baseline assessment, and routine treatment follow-up | It cannot define total risk or show plaque by itself |
| Focused follow-up | Individual triglycerides or direct LDL-C | Confirming a selected result or addressing a calculation issue | Direct LDL-C is not automatically superior to a modern calculated LDL-C |
| Risk-based or targeted | ApoB or Lp(a) | Suspected particle discordance, inherited risk, or a decision likely to change with the result | Neither test is required with every routine lipid panel |
| Specialist-directed or selected | Lipoprotein Fractionation Test, NMR | A specialist has identified a specific question that routine measurements cannot answer | Routine particle-subclass and particle-size testing is not recommended for general ASCVD risk estimation[1] |
If the result will not change risk assessment, treatment, or follow-up, an advanced test may add cost and complexity without adding useful information. Start with the clinical question, not the longest panel.
For a broader explanation of report flags, units, ranges, and trends, see How to Read Lab Results. For an overview of common blood tests and preanalytic factors, use the Complete Guide to Lab Tests and Blood Work.
There is no universal rule that every adult needs annual cholesterol testing. The Centers for Disease Control and Prevention notes that most healthy adults should have cholesterol checked every four to six years. Testing is often more frequent for people with cardiovascular disease, diabetes, a strong family history, prior abnormal results, or lipid-lowering treatment.[4]
Follow-up timing after starting or changing treatment is different from routine screening and should be based on the treatment plan. Children, adolescents, pregnant people, and those with suspected inherited lipid disorders also require age- and context-specific guidance.
Direct-access testing can make it easier to obtain baseline or follow-up information, but it does not replace clinical interpretation. Start with the question you need the test to answer, choose the smallest appropriate test set, review the exact preparation instructions, and discuss concerning or unexpected results with a qualified clinician.
Learn how the process works in Ulta’s guide to Direct Access Lab Testing. Availability, ordering requirements, collection options, pricing, and preparation instructions vary by test and location; confirm the current details shown with the selected order.
A standard lipid panel measures total cholesterol, HDL-C, and triglycerides and usually estimates LDL-C. It also allows non-HDL-C to be calculated. ApoB and Lp(a) are separate tests unless a specifically named panel includes them.
Most lipid panels include total cholesterol, LDL-C, HDL-C, and triglycerides. Reports may also show non-HDL-C, cholesterol ratios, or the equation used to estimate LDL-C.
Subtract HDL-C from total cholesterol: non-HDL-C = total cholesterol − HDL-C. The result represents cholesterol carried in all non-HDL lipoproteins, including LDL and triglyceride-rich remnant particles.
LDL-C measures cholesterol mass within LDL-related particles. ApoB approximates the number of all major atherogenic particles, including LDL, IDL, VLDL remnants, and Lp(a). They often agree but are not interchangeable.
Discordance is more common when particles carry an unusual amount of cholesterol, including with higher triglycerides, diabetes, insulin resistance, metabolic syndrome, obesity, and very low treated LDL-C. In those settings, ApoB may reveal more particles than LDL-C alone suggests.
No. HDL-C is one factor in risk assessment, but a high HDL-C does not neutralize elevated LDL-C, ApoB, or Lp(a). Risk is evaluated from the full clinical picture.
Not for every clinical lipid assessment. Nonfasting testing is acceptable in many settings, while fasting can help when triglycerides are high or a result needs confirmation. Always follow the exact instructions for the product ordered; Ulta’s current lipid panel instructions require fasting.
Direct LDL-C may be considered when a calculated result is unavailable or unreliable or when direct measurement is specifically preferred. Modern LDL-C equations are generally preferred over routine direct assays, and direct LDL does not replace ApoB or Lp(a).
Contributors include recent food intake, alcohol, diabetes, insulin resistance, obesity, hypothyroidism, kidney or liver disease, pregnancy, medications, and inherited disorders. One elevated result may need confirmation and a secondary-cause review.
Current guidance supports measuring Lp(a) at least once in adulthood. Additional testing depends on the result, family history, treatment context, and clinician judgment because Lp(a) is largely inherited and usually stable.
Most healthy adults are generally screened every four to six years, while people with prior abnormalities, cardiovascular disease, diabetes, strong family history, or treatment may need testing more often. Follow the interval recommended for your situation.
No. Cholesterol tests cannot show plaque, locate a blockage, diagnose coronary artery disease by themselves, or rule out a heart attack. Symptoms that could indicate an acute event require urgent medical evaluation.
A standard lipid panel is the foundation of cholesterol testing, but its components answer different questions. LDL-C measures cholesterol carried in LDL-related particles. Non-HDL-C broadens the view to cholesterol in all non-HDL particles. ApoB estimates atherogenic particle number. HDL-C informs risk estimation but is not a stand-alone treatment target, and triglycerides are highly responsive to metabolic, genetic, medication, and collection factors.
The most useful test is the one tied to a clear decision. Begin with routine lipid measurements, add ApoB or Lp(a) when the result could refine risk, and reserve advanced fractionation for selected specialist-directed questions. For cardiovascular testing beyond cholesterol, see the complete guide to heart health blood tests.
Editorial and commercial disclosure: Ulta Lab Tests provides access to laboratory testing. Test availability, ordering requirements, prices, preparation instructions, and collection options can change and may vary by location. Educational content should be reviewed by a qualified medical professional before publication and is not a substitute for individualized medical advice.
Originally published: August 28, 2024 | Substantively updated: August 28 2026
Important: Non-HDL-C usually does not require a separate order. It is calculated as total cholesterol minus HDL-C. Total cholesterol, LDL-C, and HDL-C are already included in the lipid panel and do not need separate product promotion in this article.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
